Darunavir Crystalline Forms for Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV-1 face challenges such as drug resistance, toxicity, and complex treatment regimens, necessitating the development of stable and effective formulations of darunavir that minimize drug interactions and maintain long-term safety and adherence.
Innovation Solution
The development of novel crystalline forms of darunavir, including Form I, Hydrate I, Solvate I, and their characterization through XRPD, DSC, and TGA analysis, which provide enhanced stability, bioavailability, and manufacturability, thereby addressing the challenges of drug resistance and treatment complexity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple different drugs are used to suppress HIV and treat other conditions, then viral suppression is achieved, but the potential for drug interactions increases
Solution Approach 1:
The patent changes the physical form parameter of darunavir from amorphous to crystalline, which modifies its dissolution rate and bioavailability characteristics. This allows for optimized dosing that may reduce drug interactions while maintaining viral suppression efficacy.
2Reliability
If potent and well-tolerated anti-retroviral therapy is used, then viral suppression is achieved, but mutations of the HIV-1 virus continue to occur
Solution Approach 1:
The patent changes the physical form parameter of darunavir from amorphous to crystalline, which modifies its dissolution rate and bioavailability characteristics. This allows for optimized dosing that may reduce drug interactions while maintaining viral suppression efficacy.
3Stability of the object's composition
If stable forms of darunavir are developed, then chemical and physical stability is improved, but manufacturing and storage requirements become more complex
Solution Approach 1:
The patent changes the physical form parameter of darunavir from amorphous to crystalline, which modifies its dissolution rate and bioavailability characteristics. This allows for optimized dosing that may reduce drug interactions while maintaining viral suppression efficacy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to crystalline forms of darunavir free base, hydrate, acetic acid solvate, esylate, besylate, hemisulfate, napsylate, hemiedisylate, tosylate, methyl ethyl ketone (MEK) solvate, methyl tetrahydrofuran (MeTHF) solvate, methyl acetate (MeOAc) solvate and ethyl formate solvate, and to pharmaceutical formulations thereof for treating viral infections.